Court allows Sandoz to launch first US biosimilar in September

By Zachary Brennan contact

- Last updated on GMT

Court allows Sandoz to launch first US biosimilar in September

Related tags: Amgen

Novartis’ Sandoz unit will begin selling a biosimilar for Amgen’s cancer treatment Neupogen on September 2, thanks to an appeals court ruling released Tuesday.

The ruling begins to set the record straight in what could be a prolonged battle over the requirements of the Affordable Care Act’s (ACA) biosimilars pathway. One particular point of contention between Sandoz and Amgen is whether or not Sandoz was required to disclose the way it intends to manufacture its biosimilar -- known as Zarxio (filgrastim-sndz), which received FDA approval in early March​.

The US Court of Appeals for the Federal Circuit said in the ruling that the manufacturing disclosure is mandatory, noting “when an applicant chooses the abbreviated pathway for regulatory approval of its biosimilar product, it is required to disclose its aBLA [abbreviated Biologic License Application] and manufacturing information to the RPS [reference product sponsor] no later than 20 days after the FDA’s notification of acceptance​.”

The ruling on Sandoz’s Zarxio (filgrastim-sndz) Tuesday follows another ruling by a California judge​ in March, which said Sandoz’s failure to provide this information to Amgen should not stop the biosimilar from coming to market.

But this latest ruling offered a more assertive opinion on what is required by the biosimilars law. “The BPCIA [Biologics Price Competition and Innovation Act] as enacted leaves no uncertainty as to which of its provisions are mandatory and which are permissive​,” the court said.

The marketing of Zarxio will come as Neupogen brought in $839m in US sales last year for Amgen, though sales have been falling as patients switched to a newer version of the drug, called Neulasta, according to Bloomberg News​.

As the majority opinion recognizes, this case requires us to ‘unravel the riddle, solve the mystery, and comprehend the enigma’ that is the BPCIA​,” the appeals court concluded, with a nod to Winston Churchill’s take on Russia in a BBC radio address.

Related news

Show more

Related products

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars